Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
Publication
, Conference
Grimm, M-O; Mcdermott, DF; Choueiri, TK; Motzer, RJ; Frontera, OA; George, S; Powles, T; Donskov, F; Harrison, MR; Rodriguez-Cid, J; Ishii, Y ...
Published in: ONCOLOGY RESEARCH AND TREATMENT
February 1, 2020
Duke Scholars
Published In
ONCOLOGY RESEARCH AND TREATMENT
EISSN
2296-5262
ISSN
2296-5270
Publication Date
February 1, 2020
Volume
43
Start / End Page
70 / 71
Publisher
KARGER
Citation
APA
Chicago
ICMJE
MLA
NLM
Grimm, M.-O., Mcdermott, D. F., Choueiri, T. K., Motzer, R. J., Frontera, O. A., George, S., … Tannir, N. M. (2020). Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC). In ONCOLOGY RESEARCH AND TREATMENT (Vol. 43, pp. 70–71). KARGER.
Grimm, Marc-Oliver, David F. Mcdermott, Toni K. Choueiri, Robert J. Motzer, Osvaldo Aren Frontera, Saby George, Thomas Powles, et al. “Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC).” In ONCOLOGY RESEARCH AND TREATMENT, 43:70–71. KARGER, 2020.
Grimm M-O, Mcdermott DF, Choueiri TK, Motzer RJ, Frontera OA, George S, et al. Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC). In: ONCOLOGY RESEARCH AND TREATMENT. KARGER; 2020. p. 70–1.
Grimm, Marc-Oliver, et al. “Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC).” ONCOLOGY RESEARCH AND TREATMENT, vol. 43, KARGER, 2020, pp. 70–71.
Grimm M-O, Mcdermott DF, Choueiri TK, Motzer RJ, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Rodriguez-Cid J, Ishii Y, Mchenry B, Rini BI, Tannir NM. Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC). ONCOLOGY RESEARCH AND TREATMENT. KARGER; 2020. p. 70–71.
Published In
ONCOLOGY RESEARCH AND TREATMENT
EISSN
2296-5262
ISSN
2296-5270
Publication Date
February 1, 2020
Volume
43
Start / End Page
70 / 71
Publisher
KARGER